Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / *W EXP 99/99/999
-
Total 13F shares
-
2,281,964
-
Share change
-
+2,281,964
-
Total reported value
-
$1,913,061
-
Price per share
-
$0.87
-
Number of holders
-
20
-
Value change
-
+$1,913,061
-
Number of buys
-
20
Institutional Holders of NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) as of Q4 2022
As of 31 Dec 2022,
NewAmsterdam Pharma Co N.V. - *W EXP 99/99/999 (NAMSW) was held by
20 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,281,964 shares.
The largest 10 holders included
HIGHBRIDGE CAPITAL MANAGEMENT LLC, Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., Ensign Peak Advisors, Inc, Exos TFP Holdings LLC, Bain Capital Life Sciences Investors, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Castle Creek Arbitrage, LLC, PEAK6 Investments LLC, and Westchester Capital Management, LLC.
This page lists
20
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.